Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission
NCT07511439Phase 4Recruiting
- Sponsor
- Rigshospitalet
- Start
- Apr 2026
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of avatrombopag, ethinyl estradiol, sponsored by Rigshospitalet. Started Apr 2026; status: recruiting.
02
Drugs
avatrombopagethinyl estradiol
Beyond the preview
Go deeper on NCT07511439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07511439.